Journal of Psychopharmacology
January 13, 2026
James Glazer, Hanna Molla, Royce Lee et al.
Lysergic acid diethylamide (LSD) has been considered as a potential treatment for depression for over 75 years, but its therapeutic potential has only recently been considered in mainstream psychiatry. Repeated ingestion of low doses of LSD ("microdoses") is thought to reduce depression, but the neurobiology underlying this effect is unknown. We previously reported that low doses of LSD...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
January 13, 2026
Caitlin Baten, Gladys Zamora, Amanda M. Klassen et al.
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder with limited treatment success in both youth and adults. Functional magnetic resonance imaging (fMRI) studies have reported partially differential patterns of activation in youth and adults diagnosed with MDD that may be attributable to age or length of illness. Following PRISMA guidelines, we searched PubMed through...
Journal of Clinical Psychopharmacology
January 12, 2026
Natia Horato, Felipe Dalvi-Garcia, Pablo E P Dutra et al.
1 citation
Treatment-resistant depression (TRD), a clinical subtype of major depressive disorder (MDD), is associated with greater severity and functional impairment, representing a significant challenge in psychiatric care. Recent studies suggest that the use of psychedelics can provide rapid and substantial improvement in the severity of depressive symptoms. Therefore, the aim of this systematic review...
OBM Integrative and Complementary Medicine
January 7, 2026
Oteja Lightheart, Helané Wahbeh
Older adults in the U.S. have higher rates of depression, stress, and chronic diseases. There is an urgent need for effective interventions to reduce depressive symptoms and enhance overall health and well-being. Meditation presents an appealing therapeutic option due to its cost-effectiveness, minimal risks, ease of use, and active patient involvement, with growing evidence indicating its...
BMC Psychiatry
January 4, 2026
Carl D. Marci, Kruti Joshi, Stevan Geoffrey Severtson et al.
2 citations
Abstract Background Treatment-resistant depression (TRD) is often characterized by inadequate response to ≥ 2 oral antidepressant treatments of adequate dose and duration during a major depressive episode (MDE). Esketamine nasal spray (ESK) was approved by the US Food and Drug Administration in 2019 for TRD in conjunction with an oral antidepressant under a Risk Evaluation and Mitigation...
2026
Yosr Ziadi, Taehwan Park
preprint
Conference poster presented at ISPOR 2026, Philadelphia, May 2026. Co-authors: Yosr Ziadi, Taehwan Park. St. John's University.
2026
Tom Bielen
preprint
Psilocybin-assisted therapy has produced promising results in clinical trials for depression, but most existing reviews treat major depressive disorder (MDD) and treatment-resistant depression (TRD) as a single category. This conflation is a problem. MDD and TRD differ in diagnostic criteria, illness severity, prior treatment failure, and likely neurobiological profile. Pooling their results...
2026
Irina Dell'Orto
preprint
Background: Psilocybin-assisted therapy (PAT) has demonstrated rapid and substantial antidepressant effects in phase 2 RCTs (Davis et al., 2021; Carhart-Harris et al., 2021), and phase 3 trials are now active (Usona uAspire, NCT06308653). However, three critical gaps remain unresolved in 2025: (1) the durability of effects beyond 12 months has not been established in a controlled design; (2)...
2026
Canyon Akromis, Lorraine Li, Kwon Mok Ko et al.
preprint
This project is a secondary analysis of data from Psilocybin in Depression Resistant to Standard Treatments (PsiDeR) study, a phase II, randomised, placebo-controlled clinical trial where participants with treatment resistant depression received either 25 mg of psilocybin or a placebo alongside psychotherapy. This research seeks to determine whether the therapeutic alliance, measured by the...
Journal of Marital and Family Therapy
2026
Matthew E. Jaurequi
ABSTRACT Mindfulness may reduce depression by supporting more satisfying relationships, yet these associations remain understudied in Latino couples. Given the overlap between mindfulness and Latino cultural values, this study tested whether trait mindfulness is linked to greater relationship satisfaction and, in turn, lower depression among Latino couples. Survey data from 293 heterosexual...
Diabetes, metabolic syndrome and obesity : targets and therapy
2026
Xiaoyan Xiu, Yingying Lin, Jiaying Lin et al.
Gestational diabetes mellitus (GDM) is a common pregnancy complication associated with substantial maternal and fetal health risks. Apart from metabolic disturbances, a confirmed GDM diagnosis often elicits anxiety, depression, and diabetes-specific distress, which may activate the hypothalamic-pituitary-adrenal (HPA) axis, exacerbate insulin resistance, and undermine glycemic regulation,...
2026
Vassilis Martiadis, Fabiola Raffone, Domenico de Berardis
preprint
BACKGROUND: Treatment-resistant depression (TRD) affects approximately one-third of patients with major depressive disorder and represents a critical clinical challenge. Esketamine (S-ketamine, Spravato), approved by FDA and EMA since 2019, and psychedelic-assisted therapies (psilocybin, MDMA) share a pharmacological feature unique among approved psychiatric treatments: they induce altered...
Journal of Medical Excellence
2026
Risha Jatal, Abhishek Samarth, Srushti Deulkar
A BSTRACT Major depressive disorder is commonly associated with suicidal ideation, while conventional antidepressants have a delayed onset of action. Ketamine has emerged as a rapid-acting antidepressant with potential anti-suicidal effects. This retrospective case series evaluated the effectiveness and tolerability of intravenous ketamine in patients with major depressive disorder and active...
Frontiers in Oncology
2026
Jing Lei, Meimei He
Mindfulness-based stress reduction (MBSR) has shown promise in improving physical and mental health in breast cancer patients, warranting further comprehensive evaluation. This meta-analysis aimed to assess the effects of MBSR compared to usual care on the physical and psychological well-being of patients with breast cancer. A systematic search of Web of Science, PubMed, Cochrane Library, and...
Open Mind
2026
Ellen Sallis, Thorsten Barnhofer, Daniel Milburn et al.
preprint
Research to date has focused largely on mindfulness-based interventions as whole treatment packages, with relatively little exploration of the specific mindfulness practices that comprise them. Understanding the effects of individual practices could offer insight into why mindfulness-based interventions work for some but not others and help identify and mitigate any adverse effects. This is in...
Topics in spinal cord injury rehabilitation
2026
Radha Korupolu, Chelsea G Ratcliff, Shrasti Lohiya et al.
This study evaluated the feasibility and acceptability of an app-guided mindfulness meditation (MM) intervention compared to a health education (HE) control for individuals with spinal cord injury (SCI) and chronic pain. A pilot randomized controlled trial recruited 60 individuals with SCI and chronic pain from local SCI outpatient clinics, national registries, and community outreach....
Clinical ophthalmology
2026
Michael Huang, Jason Sheng, Brian Yu et al.
Those diagnosed with eye disease are at a higher risk for experiencing a decreased quality of life (QOL). Meditation and breathing exercises have been linked with improvements in this area, but research in populations of eye disease patients is relatively scarce. We aim to bridge this knowledge gap by synthesizing the available evidence on the effects of meditation and breathing exercises on...
Psychological Medicine
2026
Jingjing Xie, Li Li, Xuehua Liu et al.
Abstract Background Nonsuicidal self-injury (NSSI) in adolescents with depressive disorder is characterized by recurrent impulsivity and is a predictor of future suicidal behavior, necessitating effective and feasible interventions. Mindfulness-based cognitive therapy for adolescents (MBCT-A), a first-line treatment for depression, was evaluated in this trial for its efficacy in reducing NSSI...
Neuropsychiatria i Neuropsychologia
2026
Joanna Kot, Ewa Ferensztajn-Rochowiak, Oryna Kaliuzhna et al.
Treatment-resistant depression (TRD) affects about 30% of patients with major depressive disorder and remains a major clinical challenge.The limited effectiveness of classical antidepressants suggests that the pathophysiology of TRD is complex and extends beyond the traditional monoamine hypothesis.The aim of this paper was to present current concepts of the neurobiological background of TRD...
Frontiers in Psychiatry
2026
Sonora Yun, Martijn Figee
Treatment-resistant depression (TRD) poses a significant challenge, with many patients failing to achieve remission with conventional therapies. While repetitive Transcranial Magnetic Stimulation (rTMS) is an established and effective neuromodulatory treatment for TRD, a notable proportion of patients do not fully respond. Despite the clinical utility of rTMS, response variability remains a...